top of page

ASTRAZENECA SIGNS AI RESEARCH DEAL WITH CHINA'S CSPC FOR CHRONIC DISEASES

  • NEWS Desk Global
  • Jun 13
  • 1 min read

Updated: Jun 16


AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic conditions, it said on Friday.

The deal marks the latest effort by AstraZeneca to revive its business in China, its second-biggest market, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports.

Comentarios

Ya no es posible comentar esta entrada. Contacta al propietario del sitio para obtener más información.
bottom of page